Dr Lal PathLabs buys remaining 30% stake in Centrapath Labs
In short
Dr Lal PathLabs has bought the remaining 30% stake in Centrapath Labs. The deal puts the Indore-based diagnostics business fully under PathLabs Unifiers, which is a subsidiary of Dr Lal PathLabs.
This matters because the company now has fuller control of the unit. The reporting does not say how much the deal cost or when it closed.
What the reporting says
Dr Lal PathLabs acquired the remaining 30% stake in Centrapath Labs, according to the reported summary. The deal consolidates ownership of the Indore-based healthcare and diagnostic services provider under PathLabs Unifiers, a subsidiary of Dr Lal PathLabs. The reporting does not disclose the transaction value, closing date, or whether any integration changes will follow.
Why it matters
Dr Lal PathLabs acquired the remaining 30% stake in Centrapath Labs, consolidating ownership of the Indore-based healthcare and diagnostic services provider under PathLabs Unifiers. The move should give Dr Lal PathLabs full control over the unit, which may help with integration and decision-making. The reporting does not provide the deal value or any operational changes tied to the acquisition.